SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 4609.
  • 2
    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 32531.
  • 3
    Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999; 58: 114.
  • 4
    Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 273745.
  • 5
    Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63: 9525.
  • 6
    Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 2005; 52: 40211.
  • 7
    Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 72232.
  • 8
    Lautermann D. Ankylosing spondylitis-cardiac manifestations. Clin Exp Rheumatol 2002; 20 Suppl 28: S115.
  • 9
    Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 1746.
  • 10
    Kaprove RE, Little AH, Graham DC, Rosen PS. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum 1980; 23: 5761.
  • 11
    Peters MJ, Visman I, Nielen MM, van Dillen N, Verheij RA, van der Horst-Bruinsma IE, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69: 57981.
  • 12
    Divecha H, Sattar N, Rumley A, Cherry L, Lowe G, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005; 109: 1716.
  • 13
    Van Halm VP, van Denderen JC, Peters MJ, Twisk JW, van der Paardt M, van der Horst-Bruinsma IE, et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 14737.
  • 14
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 11526.
  • 15
    Egger M, Smith DG, Altman D. Systematic reviews in health care: meta-analysis in context. London: BMJ Books; 2001.
  • 16
    Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everything: large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998; 78: 20916.
  • 17
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 18
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 19
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 20
    Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 105.
  • 21
    O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 1422.
  • 22
    French Health Products Safety Agency. French recommendations for the management of dyslipidemia in France. Saint-Denis (France): AFSSAPS; 2005.
  • 23
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106: 3143.
  • 24
    Levy L, Fautrel B, Barnetche T, Schaeverbeke T. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients: a systematic review of the literature. Clin Exp Rheumatol 2008; 26: 38995.
  • 25
    Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 35865.
  • 26
    Sattar N, McCarrey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 295763.
  • 27
    Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 48395.
  • 28
    Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989; 321: 13116.
  • 29
    Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007; 100: 3240.
  • 30
    Van Eijk IC, Peters MJ, Serne EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis 2009; 68: 3626.
  • 31
    Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1997; 9 Suppl: 1521.
  • 32
    Johnson RT, Dickersin K. Publication bias against negative results from clinical trials: three of the seven deadly sins [letter]. Nat Clin Pract Neurol 2007; 3: 5901.
  • 33
    Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004; 171: 73540.
  • 34
    Olson CM, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan JW, et al. Publication bias in editorial decision making. JAMA 2002; 287: 28258.
  • 35
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33: 24406.
  • 36
    Sari I, Okan T, Akar H, Cece H, Altay C, Secil M, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45: 2836.
  • 37
    Kang E, Choi S, Lee S, Park Y. Atherogenic lipid profile in ankylosing spondylitis [abstract]. Ann Rheum Dis 2007; 66 Suppl 2: 399.
  • 38
    Okan T, Sari I, Akar S, Cece H, Goldeli O, Guneri S, et al. Ventricular diastolic function of ankylosing spondylitis patients by using conventional pulsed wave Doppler, myocardial performance index and tissue Doppler imaging. Echocardiography 2008; 25: 4756.
  • 39
    Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008; 47: 12037.
  • 40
    Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with X-rays. Br Med J 1982; 13: 44960.
  • 41
    Radford EP, Doll R, Smith PG. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 1977; 11: 5726.
  • 42
    Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 216772.
  • 43
    Karoli N, Rebrov A. Arterial stiffness in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2009; 68 Suppl 3: 645.
  • 44
    Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47: 17759.
  • 45
    Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 2008; 75: 54853.
  • 46
    Ariza-Ariza R, Hernandez-Cruz B, Lopez-Antequera G, Navarro-Sarabia F. Frequency of atherosclerosis in patients with ankylosing spondylitis: a case-control study [abstract]. Ann Rheum Dis 2009; 68 Suppl 3: 646.
  • 47
    Khan MA, Khan MK, Kushner I. Survival among patients with ankylosing spondylitis: a life-table analysis. J Rheumatol 1981; 8: 8690.
  • 48
    Baskan BM, Sivas F, Aktktin LA, Dogan YP, Ozoran K, Bodur H. Serum homocysteine level in patients with ankylosing spondylitis. Rheumatol Int 2009; 29: 14359.
  • 49
    Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 7104.
  • 50
    Calistan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A, et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008; 196: 30612.
  • 51
    Sari I, Kebapcilar L, Alacacioglu A, Bilgir O, Yildiz Y, Taylan A, et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med 2009; 48: 13638.
  • 52
    Van Denderen JC, Peters MJ, van Halm VP, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Statin therapy might be beneficial for patients with ankylosing spondylitis [letter]. Ann Rheum Dis 2006; 65: 6956.
  • 53
    Van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60: 132430.
  • 54
    Demiralp E, Kardesoglu E, Kiralp MZ, Cebeci BS, Keskin I, Ozmen N, et al. Aortic elasticity in patients with ankylosing spondylitis. Acta Cardiol 2004; 59: 6304.
  • 55
    Peters MJ, van Eijk IC, Smulders YM, Serne EH, van der Horst-Bruinsma IE, Dijkmans BA, et al. Accelerated atherosclerosis in ankylosing spondylitis [abstract]. Ann Rheum Dis 2009; 68 Suppl 3: 159.
  • 56
    Sukenik S, Pras A, Buskila D, Katz A, Snir Y, Horowitz J. Cardiovascular manifestations of ankylosing spondylitis. Clin Rheumatol 1987; 6: 58892.
  • 57
    Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK, Ganotakis ES, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNF α treatment: correlation with disease activity. Clin Exp Rheumatol 2009; 27: 2928.
  • 58
    Court-Brown WM, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 1965; 2: 132732.
  • 59
    Wilkinson M, Bywaters EG. Clinical features and course of ankylosing spondylitis; as seen in a follow-up of 222 hospital referred cases. Ann Rheum Dis 1958; 17: 20928.
  • 60
    Huizer EE, van Eijk IC, Peters MJ, de Koning MH, van de Stadt RJ, van der Horst-Bruinsma IE, et al. The effect of etanercept treatment on the lipid profile in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2007; 66 Suppl 2: 398.
  • 61
    Gonzalez-Lopez L, Sanchez-Hernandez JD, Aguilar-Chavez EA, Cota-Sanchez AR, Lopez-Olivo MA, Villa-Manzano AI, et al. Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables. Rheumatol Int 2008; 28: 12238.
  • 62
    Lehtinen K. Cause of death in 79 patients with ankylosing spondylitis. Scand J Rheumatol 1980; 9: 1457.
  • 63
    Poddubnyy DA, Nikitina NM, Gaydukova IZ, Rebrov AP. Relationship between arterial stiffness parameters, cardiovascular risk factors and activity of systemic inflammation in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2009; 68 Suppl 3: 638.
  • 64
    Karvounaris SA, Sidiropoulos PI, Spanakis EK, Papadakis JA, Lanara SD, Dimaka A, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis [abstract]. Ann Rheum Dis 2007; 66 Suppl 2: 401.
  • 65
    Poddubnyy DA, Rebrov AP. Conventional and novel cardiovascular risk factors in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2007; 66 Suppl 2: 407.
  • 66
    Unverdi S, Goker B, Oktar S, Ozturk M, Haznedaroglu S, Ureten K, et al. Assessment of the morphologic evidence of subclinical atherosclerosis by carotid B-mode ultrasonography in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2007; 66 Suppl 2: 411.